Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

CHPA Makes Take-Back Programs Top Policy Targets Outside Washington

This article was originally published in The Tan Sheet

Executive Summary

CHPA will add its voice to the debate over local ordinances that include OTCs in mandatory drug take-back programs, says Carlos Gutierrez, senior director of state government affairs. Identifying the issue as its top non-federal policy fight, CHPA will continue working to educate consumers and support voluntary programs.

You may also be interested in...



CHPA Optimistic Voluntary Drug Takeback Efforts Will Stall Spread Of Mandates

OTC industry trade groups will more aggressively push for an education program to encourage proper disposal of Rx and OTC drugs as states consider mandating industry-funded takeback programs and a patchwork of local ordinances expands.

CHPA Optimistic Voluntary Drug Takeback Efforts Will Stall Spread Of Mandates

OTC industry trade groups will more aggressively push for an education program to encourage proper disposal of Rx and OTC drugs as states consider mandating industry-funded takeback programs and a patchwork of local ordinances expands.

OTC Drug Industry Could Stand To Gain With 'Pragmatist' In White House

With the Trump administration ahead, CHPA's highest regulatory priorities include eliminating a requirement from the Obama era that consumers get a prescription in order to pay for OTC drugs with pre-tax savings accounts and improving the Nixon-era monograph program.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS108264

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel